
Kyverna Therapeutics fell 34.4% from $7.16 to $4.70, behind the S&P 500's +10.0%. Its worst day was Dec 17 (−32.5%), and its low came Nov 5 at $4.61.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kyverna Therapeutics shares fell 32.5%, while the S&P 500 fell 1.1%.
−32.5%, the year's worst day · S&P 500 −1.1%
Story events cover the past 12 months · Times ET
EPS of $-0.80 beat the $-0.84 estimate on $0.00 revenue.
−2.9% · S&P 500 −1.7%
Kyverna Therapeutics closed at its highest level of the year, 57.1% above where the year started.
+13.3% · S&P 500 −0.2%
EPS of $-0.66 beat the $-0.73 estimate on $0.00 revenue.
+5.4% · S&P 500 +0.6%
Kyverna Therapeutics shares fell 13.5%, while the S&P 500 rose 0.4%.
−13.5% · S&P 500 +0.4%
EPS of $-0.63 beat the $-0.68 estimate on $0.00 revenue.
+0.4% · S&P 500 +0.3%
EPS of $-0.68 beat the $-0.69 estimate on $0.00 revenue.
−1.8% · S&P 500 −0.4%
Where it ended: a close of $4.70 on Nov 17, 2026.
Nothing in the past 12 months.
All KYTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KYTX and SPY from Benzinga historical bars. Not investment advice.